The ABCB1 Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from A-549 lung adenocarcinoma cells with targeted disruption of the ABCB1 gene. This loss-of-function model eliminates P-glycoprotein (P-gp) expression across a heterogeneous cell pool, avoiding single-cell clonal selection artifacts. The polyclonal format ensures retention of parental line diversity while providing robust functional knockout for population-level multidrug resistance studies.
A-549 cells are human lung adenocarcinoma epithelial cells originally isolated from a 58-year-old male. They serve as a prominent model for lung cancer biology, drug transport, and xenobiotic metabolism. A-549 cells display epithelial morphology and characteristics of alveolar type II pneumocytes, making them suitable for investigating transporter-mediated drug efflux and chemotherapy sensitivity.
ABCB1 encodes P-gp, an ATP-dependent efflux pump that exports hydrophobic drugs, contributing to multidrug resistance. Its transcription is regulated by NF-??B, p53, YB-1, PXR, HIF-1??, and CAR. P-gp activity affects intracellular drug accumulation and apoptosis resistance. The transporter is anchored to the actin cytoskeleton via ezrin, radixin, and moesin, and its stability is modulated by Hsp70, Hsp90, and PKC. Key signaling inputs include PXR/CAR xenobiotic sensing, PI3K/Akt survival, MAPK cascades, and p53 pathways.
In A-549 lung carcinoma cells, ABCB1 knockout abrogates drug efflux capability, sensitizing these cells to P-gp substrate chemotherapeutics such as doxorubicin and paclitaxel. This model directly links genetic inactivation of ABCB1 to chemosensitization, enabling dissection of P-gp-dependent and -independent resistance mechanisms. The polyclonal nature provides a more heterogeneous response landscape, better mimicking tumor biology than monoclonal isolates.
Typical applications include P-gp substrate screening, transporter pharmacology, multidrug resistance mechanistic studies, and lung cancer drug response modeling. Assays such as calcein-AM efflux, flow cytometric drug accumulation, western blotting for P-gp, RT-qPCR for ABCB1 mRNA, MTT drug sensitivity, and immunofluorescence localization are routinely employed. For further information or to inquire about custom gene-editing services, please contact Ascent Research.
